Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sovodak with or without ribavirin in patients with hepatitis C
IRCT20080901001155N30Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of sofosbuvir + daclatasvir and ribavirin in hepatitis C virus infection (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoints: Treatment response assessed by HCV RNA and Treatment of patients with hepatitis C in Guilan cohort. Started Nov 2017; status: completed.
02
Drugs
sofosbuvir + daclatasvirribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on IRCT20080901001155N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20080901001155N30.